FDA’s draft “plausible mechanism” framework gives individualized genetic therapies a clearer path to market, but questions remain, write experts at Morrison Foerster.
Opinion
Balancing benefit and burden: rethinking post-polypectomy colonoscopy surveillance strategies
Post-polypectomy colonoscopy surveillance is widely implemented to reduce colorectal cancer incidence and mortality, yet increasing evidence raises concerns about whether current strategies are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results